Dermatology

Avicanna Files US Patent Application for a Novel Cannabinoid Formulation in Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy

Friday, September 24, 2021 - 12:30pm

TORONTO, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based pharmaceuticals is pleased to announce that it has filed a provisional patent application with the United States Patent and Trademark Office, entitled "Methods for Reducing or Eliminating Incidence of Seizures and Sudden Unexpected Death in Epilepsy", on the use of a novel cannabinoid formulation (the “Formulation Candidate”).

Key Points: 
  • Avicannas proprietary formulation showed promising pre-clinical results in reducing seizures and will be developed through the companys pharmaceutical development pipeline as an epilepsy drug candidate.
  • The research findings originated from the ongoing multi-level cannabinoid-based collaboration with leading epilepsy researcher Dr. Peter Carlen at the world-renowned Krembil Research Institute at the University Health Network (UHN).
  • Avicanna intends to conduct in vivo studies in the coming months in order to formalize this provisional application.
  • If granted, this patent application will provide Avicanna with protection on the use of the Formulation Candidate within a specified ratio of cannabinoids, alone or in combination with other anti-epileptic agents.

H.I.G. Capital Acquires Aspire Pharma

Friday, September 24, 2021 - 1:05pm

), a leading global alternative investment firm with $45 billion of equity capital under management, is pleased to announce that one of its affiliates has acquired Aspire Pharma Limited (Aspire or the Company), a leading UK provider of niche generic and branded specialty pharmaceuticals, alongside its founder Graham Fraser-Pye.

Key Points: 
  • ), a leading global alternative investment firm with $45 billion of equity capital under management, is pleased to announce that one of its affiliates has acquired Aspire Pharma Limited (Aspire or the Company), a leading UK provider of niche generic and branded specialty pharmaceuticals, alongside its founder Graham Fraser-Pye.
  • The existing management team of Aspire Pharma will remain in place, with Graham Fraser-Pye taking the role of Chairman.
  • as a key investor in the future of Aspire Pharma.
  • is a leading global private equity and alternative assets investment firm with $45 billion of equity capital under management.

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

Thursday, September 23, 2021 - 1:00pm

DURHAM, N.C., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the comprehensive safety data readout as part of the Company’s B-SIMPLE4 pivotal Phase 3 study of SB206 for the treatment of molluscum contagiosum (“molluscum”).

Key Points: 
  • Scar formation was assessed by the investigator, regardless of the size of the scar, throughout the study for TEAEs, as well as occurrence.
  • The TEAEs for scarring throughout the study were slightly higher in the vehicle group (6.3%) vs. SB206 (4.7%).
  • Subjects treated with SB206 showed a lower occurrence of scarring at the Week-24 visit when compared to vehicle (4.0% in vehicle vs. 2.7% in SB206).
  • The Company plans to present topline efficacy and safety results at upcoming medical congresses and conferences.

Zelira™ Launches RAF FIVE™ Acne Treatment Products Through Its Dermatology Focused Subsidiary

Thursday, September 23, 2021 - 1:09pm

The five-product RAF FIVE line consists of the Wash Away Gel Cleanser Acne Treatment, Spot On Acne Treatment, Kick Off Hydrating Lotion Broad Spectrum SPF 30 Sunscreen, After Hours Moisturizing Lotion Acne Treatment, and Clear the Way Acne Treatment Pads.

Key Points: 
  • The five-product RAF FIVE line consists of the Wash Away Gel Cleanser Acne Treatment, Spot On Acne Treatment, Kick Off Hydrating Lotion Broad Spectrum SPF 30 Sunscreen, After Hours Moisturizing Lotion Acne Treatment, and Clear the Way Acne Treatment Pads.
  • The RAF FIVE line is Zelira's first step into the acne medication market valued at more than US$11 billion worldwide.
  • Zelira Therapeutics CEO and Managing Director, Dr. Oludare Odumosu, commented, "I am excited to announce the launch of Zelira's Dermatology subsidiary and the RAF FIVE acne treatment line of skincare products.
  • We have a unique opportunity to present a differentiated suite of proven acne treatment solutions to the US$11 billion acne treatment market where there is a high level of dissatisfaction with existing products and unmet needs.

Biohaven's Nurtec ODT Garners Greater Early-Line Use as a Preventive Therapy Among Patients with Less Severe Migraine Compared to Eli Lilly's Emgality, According to Spherix Patient-Level Data

Thursday, September 23, 2021 - 12:30pm

In the third annual audit included in Spherix's RealWorld Dynamix: Preventive Treatment in Migraine (US) service, 221 neurologists and migraine specialists provided data on 1,013 patients.

Key Points: 
  • In the third annual audit included in Spherix's RealWorld Dynamix: Preventive Treatment in Migraine (US) service, 221 neurologists and migraine specialists provided data on 1,013 patients.
  • In comparison, close to one-third of patients recently prescribed Emgality were diagnosed with chronic migraine.
  • The leading efficacy-related factor was prolonged or increased duration of migraine attacks when prescribed Emgality and persistently high or worsening migraine severity when prescribed Nurtec ODT.
  • Likely benefiting from broad use as an acute therapy, Nurtec ODT is currently being prescribed as an earlier-line preventive therapy compared to Emgality.

Galderma Announces Exclusive Agreement With Sofregen to Develop the Next Generation of Biostimulator Fillers Using Silk-Based Technology

Thursday, September 23, 2021 - 6:00am

This collaboration will further expand Galdermas capabilities built on decades of science-based aesthetics innovation and a unique heritage in biostimulator and hyaluronic acid (HA) fillers.

Key Points: 
  • This collaboration will further expand Galdermas capabilities built on decades of science-based aesthetics innovation and a unique heritage in biostimulator and hyaluronic acid (HA) fillers.
  • At Galderma, were committed to advancing dermatology through constant innovation and joining forces with other industry pioneers.
  • This agreement highlights Sofregens dedication to advancing the science of silk and will accelerate our ability to develop the next generation of biostimulator fillers with a recognized leader in this space.
  • Galderma will also have an exclusive option to acquire Sofregens Silk Voice as well as assets associated with its aesthetics business.

Serendia, LLC Files Patent Infringement Lawsuits against Cartessa and SHEnB Relating to Radio Frequency Microneedling Devices

Wednesday, September 22, 2021 - 8:46pm

The lawsuits assert that the accused produce, import and sell infringing products and services throughout the U.S.

Key Points: 
  • The lawsuits assert that the accused produce, import and sell infringing products and services throughout the U.S.
  • The infringing products include Vivace and Virtue RF, which are radio frequency ("RF") microneedling devices manufactured and/or distributed by the accused for treatment of dermatological issues.
  • Sylfirm X is the world's first and only FDA cleared Pulsed Wave and Continuous Wave RF microneedling device.
  • The lawsuits accuse infringement of four U.S. patents: 9,320,536 (titled "Method, System, and Apparatus for Dermatological Treatment.

gGastro EHR 5.0 from Modernizing Medicine® Launches with a New User Experience that Further Speeds up Documentation

Wednesday, September 22, 2021 - 5:00pm

Speeding up documentation, on average, by up to 20%, gGastro 5.0 helps doctors document patient health records more efficiently and improves staff communications and the patient experience.

Key Points: 
  • Speeding up documentation, on average, by up to 20%, gGastro 5.0 helps doctors document patient health records more efficiently and improves staff communications and the patient experience.
  • View the full release here: https://www.businesswire.com/news/home/20210922005834/en/
    The latest platforms user experience was designed to be highly intuitive, browser-agnostic, and faster than ever.
  • gGastro 5.0 delivers greater efficiencies with documentation by suggesting coding and using custom templates and Quick Notes in the Endoscopy Report Writer that can save gastroenterologists time.
  • The latest technologies are being deployed in waves reaching all existing Modernizing Medicine gGastro customers throughout the year.

Cushman & Wakefield Represents Tenant and Landlord in 96,000-SF Office/Life Sciences Headquarters Lease in San Diego

Wednesday, September 22, 2021 - 4:30pm

DMCC is surrounded by world-class shopping and dining, and is near many of San Diegos top neighborhoods.

Key Points: 
  • DMCC is surrounded by world-class shopping and dining, and is near many of San Diegos top neighborhoods.
  • Cushman & Wakefields David Odmark represented DermTech and Cushman & Wakefields Brett Ward, Brian Starck and Michael Cassolato represented Kilroy Realty in the transaction.
  • Cushman & Wakefield (NYSE: CWK) is a leading global real estate services firm that delivers exceptional value for real estate occupiers and owners.
  • Cushman & Wakefield is among the largest real estate services firms with approximately 50,000 employees in over 400 offices and 60 countries.

Hims & Hers Expands Customizable, Compounded Skincare Offerings With Hims Overnight Anti-Aging Duo, Hers Clear Skin System

Wednesday, September 22, 2021 - 1:57pm

Hims Overnight Anti-Aging Duo was developed with dermatologists to combat wrinkles and sun damage while moisturizing and nourishing skin. It includes a customizable prescription Anti-Aging Cream mixed with three clinical ingredients and available in three different strengths, as well as the nonprescription Goodnight Wrinkle Cream made with hyaluronic acid. Both the customizable prescription Anti-Aging Cream and Goodnight Wrinkle Cream will also continue to be available for purchase individually on ForHims.com. Those consumers looking to purchase the prescription cream -- as part of the Duo or individually -- will need to first complete a consultation with a healthcare provider through the Hims & Hers platform to see if a prescription treatment is medically recommended and will be able to purchase the prescription cream only if deemed appropriate by the healthcare provider. The Goodnight Wrinkle Cream is available for purchase directly from Hims without a prescription.

Key Points: 
  • Hims & Hers Health, Inc. (Hims & Hers) (NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, recently launched Hims Overnight Anti-Aging Duo and a customized Hers Clear Skin System .
  • Skincare is a lifelong journey and certainly not a one-size-fits-all proposition, said Hilary Coles, co-founder and SVP of Brand & Innovation, Hims & Hers.
  • Hims Overnight Anti-Aging Duo was developed with dermatologists to combat wrinkles and sun damage while moisturizing and nourishing skin.
  • Hers Clear Skin System provides consumers with the ability to have both clean and hydrated skin with the support of an experienced medical professional.